查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1645728

全球無血清和特種培養基市場（按產品、應用和最終用戶分類）- 機會分析和產業預測，2024 年至 2033 年

Serum Free and Specialty Media Market By Product, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

無血清和特種培養基市場規模預計在 2023 年達到 23 億美元，預計到 2033 年將達到 69 億美元，2024 年至 2033 年的複合年成長率為 11.6%。

無血清及特殊培養基市場-IMG1

無血清培養基和專用培養基是實驗室和製藥業使用的細胞培養配方，可支持多種細胞類型的生長。這種培養基不含有動物血清（例如牛）來提供生長因子，而是用化學合成的替代品替代。無血清培養基和特殊培養基用於疫苗開發、蛋白質和病毒生產以及基因治療。

為滿足對單株抗體和疫苗日益成長的需求，生物製藥行業的發展導致對無血清和專用培養基的需求激增，從而增加了市場的發展。此外，食品藥物管理局等多個監管機構已強調在生物製藥中停止使用動物源產品，這推動了無血清和特殊培養基市場的發展。目前推動市場的一個顯著趨勢是 3D 細胞培養模型培養基的開發。 3D 細胞培養模型需要模擬體內環境的細胞生長控制條件。無血清培養基和特殊培養基是專門為滿足每種細胞培養的特定需求而配製的，因此可以滿足您的 3D 模型的受控環境要求。

然而，實現無血清和專用培養基的精確配方以實現最佳細胞生長是一個耗時而複雜的過程，帶來擴充性挑戰並阻礙市場成長。相反，由於細胞療法的安全性和在治療疾病方面的巨大潛力，醫療保健領域擴大採用細胞療法，這預計將為無血清和特種培養基市場帶來豐厚的機會。根據全球最大的生物醫學圖書館美國國家醫學圖書館的審查，到2023年第一季，全球將有超過100種基因、細胞和RNA療法核准，約有3700種療法處於臨床或臨床前開發階段。該培養基有望為細胞治療方法開闢新的途徑，因為它為治療細胞的生長提供了最佳化的、無污染的環境。

部分回顧

無血清和特殊培養基市場根據產品類型、應用、最終用戶和地區進行細分。依產品類型分為CHO培養基、HEK培養基、融合瘤培養基等。根據應用，市場分為生物製藥製造、組織工程/再生醫學和其他。根據最終用戶，市場分為製藥和生物製藥公司、研究和學術機構等。按地區分析，涵蓋北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙和其他歐洲國家地區）、亞太地區（日本、中國、印度、澳洲、韓國和其他亞太地區）、拉丁美洲和中東及非洲（巴西、中國、非洲、阿拉伯和其他南美地區）。

主要發現

根據產品類型，CHO 媒體部分在 2023 年佔據了市場主導地位。

根據應用，生物製藥生產領域在 2023 年佔據了市場的最高佔有率。

根據最終用戶，製藥和生物技術公司部門在 2023 年佔據了相當大的市場。

按地區分類，預計北美將在 2023 年創造最高收益。

全球無血清和特種培養基市場的主要主要企業有賽默飛世爾、默克、丹納赫集團 (Cytiva)、賽多利斯、Biotechne、Pan-Biotec、康寧、富士膠片歐文科學、龍沙和 MP Biomedicals。這些主要企業正在採取各種關鍵發展策略，包括產品發布、業務擴張、地理擴張和投資，以在競爭激烈的市場中站穩腳跟。

相關人員的主要利益

本報告定量分析了 2023 年至 2033 年無血清和特種培養基市場細分、當前趨勢、估計趨勢和動態，並確定了一般無血清和特種培養基市場中的機會。

它為市場研究提供與市場促進因素、市場限制因素和市場機會相關的資訊。

波特五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的商業決策，並加強供應商-買家網路。

對無血清和特種培養基市場進行詳細細分分析有助於發現市場機會。

每個地區的主要國家都根據收益貢獻進行分類。

市場公司的定位有利於基準化分析，並能清楚了解市場公司的當前地位。

報告包括區域和全球無血清和特種培養基市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

此報告可進行客製化（需支付額外費用和時間表）

  • 國家、地區和全球層面的患者/流行病學資料
  • 監管指南
  • 根據客戶興趣提供額外的公司簡介
  • 按國家或地區進行的額外分析 - 市場規模和預測
  • 擴展公司簡介列表
  • 歷史市場資料
  • SWOT 分析

目錄

第 1 章 簡介

第 2 章執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 關鍵影響因素
    • 重大投資機會
  • 波特五力分析
  • 市場動態
    • 驅動程式
      • 提高生物製藥產量
      • 專門細胞培養技術的進展
      • 個人化醫療和細胞治療方法的發展
    • 限制因素
      • 克服嚴格的監管要求和高成本
    • 機會
      • 轉向無動物、永續和道德的研究方法

第 4 章 無血清培養基及特殊培養基市場（依產品分類）

  • 概述
  • CHO 培養基
  • HEK 培養基
  • 雜交融合瘤培養基
  • 其他

第5章 無血清培養基及特殊培養基市場（依應用）

  • 概述
  • 生物製藥製造
  • 組織工程與再生醫學
  • 其他

第 6 章 無血清培養基及專用培養基市場（依最終用戶）

  • 概述
  • 製藥和生物技術公司
  • 研究和學術機構
  • 其他

第 7 章 無血清和特種培養基市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲、中東和非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 前 10 家公司的產品映射
  • 競爭儀錶板
  • 競爭熱圖
  • 2023年主要企業的定位

第9章 公司簡介

  • Sartorius AG
  • Danaher Corporation
  • Fujifilm Holdings Corporation
  • Merck KGaA
  • Lonza
  • PAN-Biotech
  • Corning Incorporated
  • MP Biomedicals
  • Bio-Techne
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: A197307

The serum free and specialty media market was valued at $2.3 billion in 2023 and is estimated to reach $6.9 billion by 2033, exhibiting a CAGR of 11.6% from 2024 to 2033.

Serum Free and Specialty Media Market - IMG1

A serum-free and specialty media is a cell culture formulation used in laboratories and pharmaceutical industries to support the growth of different types of cells. This type of media does not contain animal serum such as fetal bovine serum for the supply of growth factors; instead, it is replaced by chemically synthesized alternatives. Serum-free and specialty media is utilized in vaccine development, protein & virus production, and gene therapy.

Expansion of the biopharmaceutical industry to cater to increasing demand for monoclonal antibodies and vaccines has upsurged the requirement for serum-free and specialty media, hence augmenting the development of the market. In addition, several regulatory bodies such as the Food and Drug Administration are stressing the elimination of animal-based product usage in biopharmaceuticals, which is driving the serum-free and specialty media market. A notable trend acquiring traction in the market currently is the development of media for 3D cell culture models, which require controlled conditions that mimic the in-vivo environment for cell growth. The serum-free and specialty media aligns with the controlled environment requirement of the 3D model as its formulation is particularly created to serve the specialized purpose of each cell culture.

However, achieving the accurate formulation of serum-free and specialty media for optimal cell growth is a time-consuming, complex process that presents scalability challenges and hampers the market growth. On the contrary, rise in the adoption of cell therapies in the medicine sector due to their safety and promising potential for curing diseases is expected to present lucrative opportunities for the serum-free and specialty media market. As per a review article on the National Library of Medicine-the largest biomedical library globally-by the end of the first quarter of 2023, there were more than 100 different approved gene, cell, and RNA therapies across the globe and approximately 3,700 therapies were in the clinical or preclinical development stage. As the media provides an optimized and contamination-free environment for the growth of therapeutic cells, it is projected to witness novel avenues with increasing cell therapy procedures.

Segment Review

The serum-free and specialty media market is segmented into product type, application, end user, and region. By product type, the market is segregated into CHO media, HEK media, hybridoma media, and others. As per application, it is classified into biopharmaceutical production, tissue engineering & regenerative medicine, and others. According to end user, it is classified into pharmaceutical & biopharmaceutical companies, research & academic institutes, and others. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Findings

By product type, the CHO media segment dominated the market in 2023.

As per application, the biopharmaceutical production segment held the highest share of the market in 2023.

According to end user, the pharmaceutical & biotechnology companies segment acquired a notable stake in the market in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

Major key players that operate in the global serum-free and specialty media market are Thermo Fischer, Merck KGAA, Danaher Corporation (Cytiva), Sartorius AG, Biotechne, Pan-Biotec, Corning, FUJIFILM Irvine Scientific., Lonza, and MP Biomedicals. These major players have adopted various key development strategies such as product launch, expansion, geographical expansion, and investment to strengthen their foothold in the competitive market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the serum free and specialty media market analysis from 2023 to 2033 to identify the prevailing serum free and specialty media market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the serum free and specialty media market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global serum free and specialty media market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Product

  • CHO Media
  • HEK Media
  • Hybridoma Media
  • Others

By Application

  • Biopharmaceutical Production
  • Tissue Engineering and Regenerative Medicine
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of Asia-Pacific

Key Market Players:

    • Corning Incorporated
    • MP Biomedicals
    • Fujifilm Holdings Corporation
    • Lonza
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • PAN-Biotech
    • Bio-Techne
    • Sartorius AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in Biopharmaceutical Production
      • 3.4.1.2. Advancements in Specialty Cell Culture Technology
      • 3.4.1.3. Growth In Personalized Medicine and Cell-Based Therapies
    • 3.4.2. Restraints
      • 3.4.2.1. Navigating Strict Regulatory Requirements and High Costs
    • 3.4.3. Opportunities
      • 3.4.3.1. The shift towards animal-free, sustainable, and ethical research practices

CHAPTER 4: SERUM FREE AND SPECIALTY MEDIA MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CHO Media
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. HEK Media
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Hybridoma Media
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: SERUM FREE AND SPECIALTY MEDIA MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Biopharmaceutical Production
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Tissue Engineering and Regenerative Medicine
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: SERUM FREE AND SPECIALTY MEDIA MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Research and Academic Institutes
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SERUM FREE AND SPECIALTY MEDIA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Product
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Product
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of Asia-Pacific
      • 7.5.5.4.1. Market size and forecast, by Product
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Sartorius AG
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Danaher Corporation
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Fujifilm Holdings Corporation
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Merck KGaA
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Lonza
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. PAN-Biotech
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Corning Incorporated
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. MP Biomedicals
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Bio-Techne
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Thermo Fisher Scientific Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance